Kelun-Biotech
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Anika Sharma
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...